Posición oficial de la Sociedad Chilena de Climaterio para el manejo clínico de la mujer climatérica

The health of many women is affected in the climacteric period, either by symp-toms that deteriorate their life quality (QL) or by chronic diseases that affect their life expectancy. Therefore, it is mandatory to evaluate these two aspects, having as core objectives for any eventual therapeutic inte...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	BLÜMEL M,JUAN ENRIQUE, ARAVENA P,HERNÁN, BRANTES G,SERGIO, CRUZAT T,LUIS, LAVÍN A,PABLO, MONTAÑO V,RENÉ, NAVARRETE A,ISIDORO, OSORIO F,EDUARDO
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2010
Materias:	Climacteric Gonadal hormones Menopause Metabolic syndrome X
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000500017
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872010000500017
record_format	dspace
spelling	oai:scielo:S0034-988720100005000172010-07-12Posición oficial de la Sociedad Chilena de Climaterio para el manejo clínico de la mujer climatéricaBLÜMEL M,JUAN ENRIQUEARAVENA P,HERNÁNBRANTES G,SERGIOCRUZAT T,LUISLAVÍN A,PABLOMONTAÑO V,RENÉNAVARRETE A,ISIDOROOSORIO F,EDUARDO Climacteric Gonadal hormones Menopause Metabolic syndrome X The health of many women is affected in the climacteric period, either by symp-toms that deteriorate their life quality (QL) or by chronic diseases that affect their life expectancy. Therefore, it is mandatory to evaluate these two aspects, having as core objectives for any eventual therapeutic intervention, the improvement of QL and the reduction of cardiovascular risk and fractures. To evaluate QL it is mandatory to follow structured interviews that weigh systematically climacteric symptoms such as the Menopause Rating Scale (MRS). The paradigm of the metabolic syndrome constitutes a suitable frame to evaluate cardiovascular risk. Age, a low body weight, a history of fractures and steroid use are risk factors for fractures. A proper evaluation will allow the detection of patients with a low QL or a high risk for chronic disease, therefore identifying those women who require therapy. The clinical management should include recommendations to improve lifestyles, increase physical activity, avoidance of smoking and to follow a low calorie diet rich in vegetables and fruits. Hormonal therapy is the most effcient treatment to improve the QL and its risk is minimized when it is used in low doses or by the transdermal route. Tibolone is an alternative, especially useful in patients with mood disorders and sexual dysfunction. Vaginal estrogens are also a good option, when urogenital symptoms are the main complaint. Some antidepressants can be an effective therapy in patients with vasomotor symptoms who are not willing or cannot use estrogens. The effectiveness of any alternative therapy for menopausal symptoms has not been demonstrated. Dyslipidemia, hypertension, obesity and insulin resistance should be managed ac-cording to guidelines. Calcium and vitamin D have positive effects on bone density and certain tendency to reduce vertebral fractures. Bisphosphonates decrease the risk of vertebral fractures.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.138 n.5 20102010-05-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000500017es10.4067/S0034-98872010000500017
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Climacteric Gonadal hormones Menopause Metabolic syndrome X
spellingShingle	Climacteric Gonadal hormones Menopause Metabolic syndrome X BLÜMEL M,JUAN ENRIQUE ARAVENA P,HERNÁN BRANTES G,SERGIO CRUZAT T,LUIS LAVÍN A,PABLO MONTAÑO V,RENÉ NAVARRETE A,ISIDORO OSORIO F,EDUARDO Posición oficial de la Sociedad Chilena de Climaterio para el manejo clínico de la mujer climatérica
description	The health of many women is affected in the climacteric period, either by symp-toms that deteriorate their life quality (QL) or by chronic diseases that affect their life expectancy. Therefore, it is mandatory to evaluate these two aspects, having as core objectives for any eventual therapeutic intervention, the improvement of QL and the reduction of cardiovascular risk and fractures. To evaluate QL it is mandatory to follow structured interviews that weigh systematically climacteric symptoms such as the Menopause Rating Scale (MRS). The paradigm of the metabolic syndrome constitutes a suitable frame to evaluate cardiovascular risk. Age, a low body weight, a history of fractures and steroid use are risk factors for fractures. A proper evaluation will allow the detection of patients with a low QL or a high risk for chronic disease, therefore identifying those women who require therapy. The clinical management should include recommendations to improve lifestyles, increase physical activity, avoidance of smoking and to follow a low calorie diet rich in vegetables and fruits. Hormonal therapy is the most effcient treatment to improve the QL and its risk is minimized when it is used in low doses or by the transdermal route. Tibolone is an alternative, especially useful in patients with mood disorders and sexual dysfunction. Vaginal estrogens are also a good option, when urogenital symptoms are the main complaint. Some antidepressants can be an effective therapy in patients with vasomotor symptoms who are not willing or cannot use estrogens. The effectiveness of any alternative therapy for menopausal symptoms has not been demonstrated. Dyslipidemia, hypertension, obesity and insulin resistance should be managed ac-cording to guidelines. Calcium and vitamin D have positive effects on bone density and certain tendency to reduce vertebral fractures. Bisphosphonates decrease the risk of vertebral fractures.
author	BLÜMEL M,JUAN ENRIQUE ARAVENA P,HERNÁN BRANTES G,SERGIO CRUZAT T,LUIS LAVÍN A,PABLO MONTAÑO V,RENÉ NAVARRETE A,ISIDORO OSORIO F,EDUARDO
author_facet	BLÜMEL M,JUAN ENRIQUE ARAVENA P,HERNÁN BRANTES G,SERGIO CRUZAT T,LUIS LAVÍN A,PABLO MONTAÑO V,RENÉ NAVARRETE A,ISIDORO OSORIO F,EDUARDO
author_sort	BLÜMEL M,JUAN ENRIQUE
title	Posición oficial de la Sociedad Chilena de Climaterio para el manejo clínico de la mujer climatérica
title_short	Posición oficial de la Sociedad Chilena de Climaterio para el manejo clínico de la mujer climatérica
title_full	Posición oficial de la Sociedad Chilena de Climaterio para el manejo clínico de la mujer climatérica
title_fullStr	Posición oficial de la Sociedad Chilena de Climaterio para el manejo clínico de la mujer climatérica
title_full_unstemmed	Posición oficial de la Sociedad Chilena de Climaterio para el manejo clínico de la mujer climatérica
title_sort	posición oficial de la sociedad chilena de climaterio para el manejo clínico de la mujer climatérica
publisher	Sociedad Médica de Santiago
publishDate	2010
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000500017
work_keys_str_mv	AT blumelmjuanenrique posicionoficialdelasociedadchilenadeclimaterioparaelmanejoclinicodelamujerclimaterica AT aravenaphernan posicionoficialdelasociedadchilenadeclimaterioparaelmanejoclinicodelamujerclimaterica AT brantesgsergio posicionoficialdelasociedadchilenadeclimaterioparaelmanejoclinicodelamujerclimaterica AT cruzattluis posicionoficialdelasociedadchilenadeclimaterioparaelmanejoclinicodelamujerclimaterica AT lavinapablo posicionoficialdelasociedadchilenadeclimaterioparaelmanejoclinicodelamujerclimaterica AT montanovrene posicionoficialdelasociedadchilenadeclimaterioparaelmanejoclinicodelamujerclimaterica AT navarreteaisidoro posicionoficialdelasociedadchilenadeclimaterioparaelmanejoclinicodelamujerclimaterica AT osoriofeduardo posicionoficialdelasociedadchilenadeclimaterioparaelmanejoclinicodelamujerclimaterica
_version_	1718436506901676032

Posición oficial de la Sociedad Chilena de Climaterio para el manejo clínico de la mujer climatérica

Ejemplares similares